SLC5A2 and type 2 diabetes mellitus: Moreover, in db/db mice with type 2 diabetes, a low dose of SGLT2 inhibitor–which, unlike a higher dose, did not affect hyperglycemia and glycosuria–was still able to reduce albuminuria and mesangial expansion in the same way as a higher dose (Maki et al., 2019).